Acetylcysteine + Paracetamol + Phenylephrine
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Common Cold
Conditions
Common Cold
Trial Timeline
Sep 20, 2024 → Apr 30, 2025
NCT ID
NCT05070650About Acetylcysteine + Paracetamol + Phenylephrine
Acetylcysteine + Paracetamol + Phenylephrine is a phase 3 stage product being developed by Sandoz Group for Common Cold. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05070650. Target conditions include Common Cold.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05070650 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Common Cold